Vaxcyte Q3 2026 Results: Net Loss of $297M, Loss Widens
Vaxcyte, Inc. is a large accelerated filer in the clinical or preclinical stages of vaccine development, reporting 158,299,981 shares of common stock outstanding as of November 2, 2026. The company continues to incur significant net losses and requires substantial additional funding to advance its pneumococcal conjugate vaccine candidates and cell-free protein synthesis platform.
- Key figure
- Net loss $297M